Abstracts tagged "Biomarkers"

Abstract Number: 1898 • ACR Convergence 2022
Radiographic Osteoarthritis Progression Can Be Predicted via Pyrosequencing Analysis of Baseline Peripheral Blood
Chris Dunn¹, Cassandra Velasco², Leoni Schlupp³, Emmaline Prinz³, Vladislav Izda⁴, Liubov Arbeeva⁵, Yvonne Golightly⁶, Amanda Nelson⁶ and Matlock Jeffries³, ¹University of Oklahoma Health Sciences Center, Edmond, OK, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, New York, NY, ⁵University of North Carolina Chapel Hill, Chapel Hill, NC, ⁶UNC School of Medicine, Chapel Hill, NC
Background/Purpose: Knee osteoarthritis (OA) is a heterogeneous disease characterized by a variety of clinical and molecular phenotypes. However, we do not yet have robust biomarkers…
Abstract Number: 2099 • ACR Convergence 2022
Drug Repurposing for Treating Lupus Nephritis Based on Transcriptome Profiling and Autoimmunity-Related Serological Markers
Ioannis Parodis¹, Julius Lindblom¹, Daniel Toro-Domínguez², Elena Carnero-Montoro², Maria Orietta Borghi³, Jessica Castillo⁴, Yvonne Enman⁵, Chandra Mohan⁴, Marta Alarcon-Riquelme² and Guillermo Barturen², ¹Karolinska Institutet, Stockholm, Sweden, ²Center for Genomics and Oncological Research (GENYO), Granada, Spain, ³Università degli Studi di Milano and Istituto Auxologico Italiano, Milano, Italy, ⁴University of Houston, Houston, TX, ⁵Karolinska Institutet, Sundbyberg, Sweden
Background/Purpose: LN is one of the most severe organ manifestations of SLE and constitutes an important cause of morbidity and death among patients with SLE…
Abstract Number: 2252 • ACR Convergence 2022
Higher Matrix Metalloproteinase Levels Are Predictive of Incident Interstitial Lung Disease Among a Cohort of US Veterans with Rheumatoid Arthritis
Brent Luedders¹, Dana Ascherman², Joshua Baker³, Michael Duryee¹, Yangyuna Yang¹, Punyasha Roul⁴, Katherine Wysham⁵, Paul Monach⁶, Andreas Reimold⁷, Gail Kerr⁸, Gary Kunkel⁹, Grant Cannon¹⁰, Jill Poole¹, Geoffrey Thiele¹, Ted Mikuls¹¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pittsburgh, Pittsburgh, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴UNMC, Omaha, NE, ⁵VA Puget Sound/University of Washington, Seattle, WA, ⁶VA Boston Healthcare System, Boston, MA, ⁷University of Texas Southwestern Medical Center, Dallas, TX, ⁸Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁹University of Utah, Salt Lake City, UT, ¹⁰Retired, Salt Lake City, UT, ¹¹Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Matrix metalloproteinases (MMPs) degrade extracellular matrix and have been implicated to play a role in a number of fibrotic processes. Specifically, MMPs have been…
Abstract Number: 0027 • ACR Convergence 2022
Associations of Serum C3f with Selected Biomarkers and Radiographic and Clinical Features of Knee Osteoarthritis
Yulia Liem¹, Andrew Judge¹, Khadija Ourradi¹, Dominique de Seny², Yunfei Li¹ and Mohammed Sharif¹, ¹University of Bristol, Bristol, United Kingdom, ²University of Liège, Liège, Belgium
Background/Purpose: C3 complement fragment (C3f) has been identified as a potential biomarker for evaluating osteoarthritis (OA). C3f is released during the catabolic degradation of C3b…
Abstract Number: 0304 • ACR Convergence 2022
Rheumatoid Arthritis Patients Who Switched Treatment from Adalimumab to Upadacitinib Demonstrate a Robust Reduction of Inflammation-related Biomarkers: Proteomics Analysis from the SELECT-COMPARE Phase 3 Study
Thierry Sornasse¹, Fang Cai², Heidi Camp³, In-Ho Song⁴ and Iain B McInnes⁵, ¹AbbVie, South San Francisco, CA, ²AbbVie, Redwood City, CA, ³Abbvie, Winnetka, IL, ⁴AbbVie, Inc., North Chicago, IL, ⁵Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom
Background/Purpose: Upadacitinib 15 mg QD (UPA), an oral JAK inhibitor, showed greater efficacy compared to adalimumab (ADA) in patients (pts) with active rheumatoid arthritis (RA)…
Abstract Number: 0540 • ACR Convergence 2022
Evaluation of Traditional Laboratory Markers as Predictors of Renal Flares: A Post-hoc Analysis of Four Phase III Clinical Trials of SLE
Sandra Jägerback¹, Alvaro Gomez¹ and Ioannis Parodis², ¹Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden
Background/Purpose: In patients with systemic lupus erythematosus (SLE), renal involvement is associated with high morbidity, and renal flare is a major contributing factor to poor…
Abstract Number: 0667 • ACR Convergence 2022
Correlation Matrices Visualize Differential Degree of Cell and Pathway Heterogeneity in Skin of Cutaneous Lupus Erythematosus Treatment Subgroups
Felix Chin¹, Thomas Vazquez², Josh Dan³, DeAnna Diaz⁴, Grant Sprow⁵, Jay Patel⁶, Nilesh Kodali⁷, Rui Feng⁸ and Victoria Werth⁹, ¹University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ²FIU Wertheim College of Medicine, Virginia Beach, VA, ³Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ⁴Philadelphia College of Medicine, Philadelphia, PA, ⁵Albert Einstein College of Medicine, Philadelphia, PA, ⁶Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PN, ⁷New Jersey Medical School, Coppell, TX, ⁸University of Pennsylvania, Philadelphia, ⁹University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Background/Purpose: First-line treatment for cutaneous lupus erythematosus involves the use of antimalarials. Treatment response is highly variable with some patients responding well to hydroxychloroquine (HCQ),…
Abstract Number: 0977 • ACR Convergence 2022
Effect of Belimumab (BEL) on B-cells and Serological Biomarkers for SLE: Results of the Large Integrated Analysis BEL Summary of Lupus Efficacy (Be-SLE)
Jason S Knight¹, Winn Walter Chatham², Christine Henning³, Julia H N Harris⁴, Andre Van Maurik⁵, Roger A Levy⁶ and David Pisetsky⁷, ¹University of Michigan, Division of Rheumatology, Ann Arbor, MI, ²University of Alabama at Birmingham, Clinical Immunology and Rheumatology, Birmingham, AL, ³GlaxoSmithKline, Global Medical Affairs, Durham, NC, ⁴GlaxoSmithKline, Immunology Biostatistics, Brentford, United Kingdom, ⁵GlaxoSmithKline, Clinical Pharmacology and Experimental Medicine, Stevenage, United Kingdom, ⁶GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, ⁷Duke University Medical Center, Durham, NC
Background/Purpose: Serological and cellular biomarkers are used in clinical practice to guide the management of SLE. Increased levels of anti-dsDNA and decreased levels of complement…
Abstract Number: 1232 • ACR Convergence 2022
Reliability and Validity of Single Axial Slice vs. Multiple Slice Quantitative Measurement of the Volume of Effusion-Synovitis on 3T Knee MRI in Knees with Osteoarthritis
Greg Gilles¹, Arjun Vohra¹, Chelsea Caruso¹, Dagoberto Robles¹, Mihra Taljanovic¹, Jeffrey Duryea², Erin Ashbeck¹, Edward Bedrick³ and Kent Kwoh⁴, ¹University of Arizona Arthritis Center, Tucson, AZ, ²Brigham and Women's Hospital, Boston, MA, ³Department of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, ⁴University of Arizona, Tucson, AZ
Background/Purpose: Effusion-synovitis (ES) on knee MRI has been identified as an important biomarker of OA. Semi-automated software methods offer objective measurements of ES volume on…
Abstract Number: 1500 • ACR Convergence 2022
Investigating Serum Lipids Classifying Psoriatic Arthritis Disease Activity Using Solid Phase Microextraction – Liquid Chromatography – High-Resolution Mass Spectrometry
John Koussiouris¹, Nikita Looby², Max Kotlyar³, Vathany Kulasingam⁴, Igor Jurisica⁵ and Vinod Chandran⁶, ¹Department of Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³Osteoarthritis Research Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute/ Data Science Discovery Centre for Chronic Diseases, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁴Department of Laboratory Medicine and Pathobiology, University of Toronto/ Division of Clinical Biochemistry, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada, ⁵Osteoarthritis Research Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute, University Health Network/ Departments of Medical Biophysics and Computer Science, University of Toronto, Toronto, ON, Canada, ⁶Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: Psoriasis is an inflammatory skin disease that affects over 7.25 million Americans and 1.25 million Canadians. Approximately 25% of psoriasis patients, have an inflammatory…
Abstract Number: 1685 • ACR Convergence 2022
The Presence of Anti-MAA Antibodies to Extracellular Matrix Proteins in Synovial Fluid and Sera of Patients with Rheumatoid Arthritis
Alexandra Taylor¹, Michael Duryee², Carlos Hunter², nozima Aripova², Ted Mikuls³ and Geoffrey Thiele², ¹Creighton University School of Medicine, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Antibodies to malondialdehyde-acetaldehyde protein adducts (MAA) are increased in both the serum and synovial joint fluid from patients with Rheumatoid Arthritis (RA). These antibodies…
Abstract Number: 1901 • ACR Convergence 2022
What Does Radiographic Minimum JSW Actually Measure? Comparison of Radiographic and MRI Measures Using Data from the OAI
Alan Brett¹, Michael Bowes² and Philip G Conaghan³, ¹Stryker, Austin, TX, ²Stryker, Manchester, United Kingdom, ³University of Leeds, Leeds, United Kingdom
Background/Purpose: Change in radiographic joint space width (JSW) is used as a surrogate for cartilage loss and recognized by regulatory bodies as a measure of…
Abstract Number: 2104 • ACR Convergence 2022
The Use of Cell-bound Complement Activation Product to Assess Disease Activity in SLE
Jennifer Rogers¹, Amanda Eudy², Roberta Alexander³, David Pisetsky⁴, John Conklin³, Kai Sun⁵, Lisa Criscione-Schreiber⁶, Jayanth Doss⁵, Rebecca Sadun⁵, Mithu Maheswaranathan¹ and Megan Clowse⁵, ¹Duke, Durham, NC, ²Duke University, Raleigh, NC, ³Exagen, Inc., Vista, CA, ⁴Duke University Medical Center, Durham, NC, ⁵Duke University, Durham, NC, ⁶Duke University School of Medicine, Durham, NC
Background/Purpose: Manifestations of SLE can be divided into two subtypes. Type 1 SLE includes classic SLE manifestations that are driven by autoimmune inflammatory mechanisms. Type…
Abstract Number: 2253 • ACR Convergence 2022
Sputum Cytokines Are Elevated in Rheumatoid Arthritis-Associated Interstitial Lung Disease
Timothy Wilson¹, Kevin D Deane², Jonathan Dekermanjian², Joyce Lee², Marie Feser³, Stephen Humphries⁴, Joshua Solomon⁴ and Kristen Demoruelle³, ¹University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ²University of Colorado Denver Anschutz Medical Campus, Denver, CO, ³University of Colorado Anschutz Medical Campus, Aurora, CO, ⁴National Jewish Health, Denver, CO
Background/Purpose: Interstitial lung disease (ILD) is a well-recognized comorbidity in rheumatoid arthritis (RA) that contributes significantly to morbidity and mortality. ILD is diagnosed in up…
Abstract Number: 0029 • ACR Convergence 2022
Characterizing the Anti-fibrotic Effect of Tofacitinib in TGF-β Stimulated Fibroblast-like Synoviocytes from Patients with OA
Sofie Falkenløve Madsen¹, Sarah Madsen², Elle Hollaar³, Thorbjørn Gantzel⁴, Anne-Christine Bay-Jensen³ and Christian Thudium³, ¹University of Copenhagen / Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience, University of Copenhagen, Herlev, Denmark, ³Nordic Bioscience, Herlev, Denmark, ⁴Gentofte Hospital, Gentofte, Denmark
Background/Purpose: Many osteoarthritis (OA) patients develop fibrosis of the synovial membrane leading to joint swelling, stiffness, and pain. Synovial fibroblasts activated in the synovial membrane…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].